卡麦角林在垂体腺瘤治疗中的临床应用  

Clinical Application of Cabergoline in the Treatment of Pituitary Adenoma

作　　者：马晓婧 高素敏 柳林[2] MA Xiaojing;GAO Su-min;LIU Lin(Department of Internal Medicine,Weifang Medical University,Weifang 261053,China;Department of Endocrinology,Weifang People's Hospital,Weifang261053,China)

机构地区：[1]潍坊医学院内科学教研室,山东潍坊261053 [2]潍坊市人民医院内分泌科,山东潍坊261041

出　　处：《药物生物技术》2022年第6期657-660,共4页Pharmaceutical Biotechnology

基　　金：山东省医药卫生发展项目(No.2015WS0076);潍坊市卫健委科研项目(No.WFWSJK-2021-264)。

摘　　要：多巴胺受体(Dopamine receptors,DRs)在垂体腺瘤中的表达是多巴胺受体激动剂(Dopamine receptor agonists,DAs)治疗的分子基础,催乳素(Prolactin,PRL)腺瘤高度表达多巴胺D2受体,其他类型垂体腺瘤也不同程度表达DRs。卡麦角林(Cabergoline,CAB)可有效激动D2受体,被用于PRL腺瘤的一线治疗已有几十年的历史,在其他类型垂体腺瘤中的应用也有了越来越多的报道。文章就CAB的作用机制及在垂体腺瘤中的临床应用作一综述。The expression of dopamine receptors(DRs) in pituitary adenomas is the molecular basis for the treatment of dopamine receptor agonists(DAs).Prolactinomas highly express dopamine D2 receptor, and other types of pituitary adenomas also express DRs to varying degrees.Cabergoline(CAB),which effectively activates D2 receptors, has been used in the first-line treatment of prolactinoma for decades, and has been increasingly reported in other types of pituitary adenomas.This article reviews the mechanism of CAB and its clinical application in pituitary adenoma.

关 键 词：卡麦角林 垂体腺瘤 催乳素腺瘤 多巴胺受体激动剂 

分 类 号：R739.4[医药卫生—肿瘤]